Rituxan

Fiji Cloudbreak wave ocean surf

Biotech

Candid flashes big ambitions with $370M debut

Candid’s launch combines fundraising and the acquisition of two biotechs, Vignette Bio and TRC 2004, along with their lead assets.

Darren Incorvaia Sep 9, 2024 9:00am

Unum Therapeutics

FDA puts Unum T cell therapy trial on hold after adverse events

Jul 3, 2019 10:52am

Forty Seven’s anti-CD47 combo shows promise in non-Hodgkin lymphoma

Nov 1, 2018 10:28am

Oslo Norway

Cancer player Nordic Nanovector stokes takeover talk

Feb 21, 2017 6:01am

Novartis HQ

Novartis goes after Roche’s biggest earner Rituxan in Europe

May 25, 2016 6:43am